Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation. Without adequate treatment, patients with RA will develop joint deformity and progressive functional impairment. With the implementation of treat-to-target strategies and availability of biologic therapies, the outcomes for patients with RA have significantly improved...
The development of nanoscale molecular probes capable of diagnosis, characterization, and clinical treatment of disease is leading to a new generation of imaging technologies. Such probes are particularly relevant to inflammation, where the detection of subclinical, early disease states could facilitate speedier detection that could yield enhanced, tailored therapies...
and other chronic and disabling rheumatic diseases. ACKNOWLEDGMENTS Iain B. McInnes acknowledges support from Arthritis Research UK for the ongoing rheumatology program in University of Glasgow ... Healthcare Ltd. Support for this assistance was funded by Novartis Pharma. Philip Mease and Iain B. McInnes meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this
ORCID ID profile, Ewan Hunter2, Scottish Early Rheumatoid Arthritis Inception cohort Investigators, Aroul S. Ramadass2, Jayne Green2, Alexandre Akoulitchev2, Iain B. McInnes†3 and Carl S. Goodyear†3 ... could be a first step toward personalized medicine in RA. Notes Iain B. McInnes and Carl S. Goodyear are senior authors Abbreviations GWAS: genome wide association study EULAR: European League
Scholar Search for Iain B. McInnes in:PubMed • Google Scholar Search for Philip J. Mease in:PubMed • Google Scholar Search for Lawrence Rasouliyan in:PubMed • Google Scholar Search for Erhard Quebe
article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Peter Nash, Iain B. McInnes, Philip J. Mease, Howard Thom, Kunal Gandhi ... , UK, and was funded by Novartis Pharma AG, Basel, Switzerland. Disclosures. Peter Nash has received grant/ research support and consulting fees from Novartis. Iain B. McInnes has received consulting
& Steffen M. JuglNovartis Pharmaceuticals Corporation, East Hanover, NJ, USALuminita Pricop & Kunal K. Gandhi AuthorsSearch for Iain B. McInnes in:PubMed • Google Scholar Search for Philip J. Mease in:PubMed ... contents. All authors read and approved the final manuscript. Corresponding author Correspondence to Iain B. McInnes. Ethics declarations Ethics approval and consent to participate This study was
WehrmanBotnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UKPeter C. Taylor AuthorsSearch for Iain B. McInnes in:PubMed • Google ... . Corresponding author Correspondence to Iain B. McInnes. Ethics declarations Ethics approval and consent to participate Whole blood samples from healthy volunteers were obtained under a protocol approved by
Pharmaceuticals Corporation, East Hanover, NJ, USARadhika Kajekar & Luminita Pricop AuthorsSearch for Peter Nash in:PubMed • Google Scholar Search for Philip J. Mease in:PubMed • Google Scholar Search for Iain B ... . McInnes in:PubMed • Google Scholar Search for Proton Rahman in:PubMed • Google Scholar Search for Christopher T. Ritchlin in:PubMed • Google Scholar Search for Ricardo Blanco in:PubMed • Google Scholar
A better understanding of cytokine biology over the last two decades has allowed the successful development of cytokine inhibitors against tumour necrosis factor and interleukin (IL)-1 and IL-6. The introduction of these therapies should be considered a breakthrough in the management of several rheumatic diseases. However, many patients will exhibit no or only partial response to...
, Glasgow Biomedical Research Centre, University of Glasgow, UKIain B McInnes AuthorsSearch for Cem Gabay in:PubMed • Google Scholar Search for Iain B McInnes in:PubMed • Google Scholar Corresponding
, Glasgow Biomedical Research Centre, University of Glasgow, UKIain B McInnes AuthorsSearch for Cem Gabay in:PubMed • Google Scholar Search for Iain B McInnes in:PubMed • Google Scholar Corresponding
Alarmins S100A8 and S100A9 are endogenous molecules released in response to environmental triggers and cellular damage. They are constitutively expressed in immune cells such as monocytes and neutrophils and their expression is upregulated under inflammatory conditions. The molecular mechanisms that regulate inflammatory pathways in tendinopathy are largely unknown therefore...
Early diagnosis and treatment of rheumatoid arthritis are associated with improved outcomes but current diagnostic tools such as rheumatoid factor or anti-citrullinated protein antibodies have shown limited sensitivity. In this pilot study we set out to establish a panel of urinary biomarkers associated with rheumatoid arthritis using capillary electrophoresis coupled to mass...
AuthorsSearch for Iain B McInnes in:PubMed • Google Scholar Corresponding author Correspondence to Iain B McInnes. Additional information Competing interests None declared. Rights and permissions